前立腺特異抗原（PSA）検査の世界市場レポート 2025年

前立腺特異抗原（PSA）検査市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR11.9％で72億9,000万米ドルに成長します。予測期間の成長は、検査精度の進歩、個別化医療アプローチ、個別化医療アプローチ、世界の高齢化などに起因すると考えられます。予測期間の主な動向には、バイオマーカーの組み合わせへのシフト、技術革新、ポイントオブケア検査、デジタルヘルス統合、早期発見と予防への注力などがあります。

前立腺特異抗原（PSA）検査市場の拡大予測は、前立腺がんの罹患率の増加によって促進されます。前立腺がんは、男性生殖器系の前立腺に影響を及ぼすもので、早期発見とリスク評価が必要な疾患です。PSA検査は、血流中のPSA値を測定する前立腺がんのスクリーニング・ツールとして普及しています。2023年3月に米国臨床腫瘍学会（ASCO）が発表した最近の報告によると、米国だけでも推定288,300人の男性が前立腺がんと診断され、2023年には約34,700人がこの病気で命を落とすことが明らかになった。世界全体では、2020年に約1,414,259人が前立腺がんと診断されると予測されています。その結果、前立腺がんの有病率の上昇がPSA検査市場の成長の原動力となっています。

慢性疾患の増加はPSA検査需要の急増に寄与しています。慢性疾患は、継続的な注意と管理を必要とする長引く病状を特徴とし、前立腺がんもそのような病状の1つです。PSA検査は、前立腺がんのスクリーニング、診断、進行モニタリングのための極めて重要なツールとして浮上しています。2022年に国立医学図書館が発表した予測では、少なくとも1つの慢性疾患を有する50歳以上の患者数は99.5％増加し、2050年には1億4,266万人に達すると予測されています。さらに、多疾患合併症の有病率は91.16％増加し、2050年には1,496万8,000人に達すると予測されています。したがって、慢性疾患の増加は、PSA検査市場を促進する態勢を整えています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界前立腺特異抗原（PSA）検査PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の前立腺特異抗原（PSA）検査市場：成長率分析
• 世界の前立腺特異抗原（PSA）検査市場の実績：規模と成長, 2019-2024
• 世界の前立腺特異抗原（PSA）検査市場の予測：規模と成長, 2024-2029, 2034F
• 世界前立腺特異抗原（PSA）検査総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の前立腺特異抗原（PSA）検査市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 臨床検査改善法改正（CLIA）
• 酵素免疫測定法（ELISA）
• 蛍光免疫測定法（FIA）
• その他のタイプ
• 世界の前立腺特異抗原（PSA）検査市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• スクリーニング
• 治療後のモニタリング
• その他の用途
• 世界の前立腺特異抗原（PSA）検査市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 診断センター
• 調査機関
• その他のエンドユーザー
• 世界の前立腺特異抗原（PSA）検査市場、臨床検査改善法（CLIA）のサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• CLIA免除テスト
• 非CLIA検査
• 世界の前立腺特異抗原（PSA）検査市場、酵素免疫測定法（ELISA）のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• サンドイッチELISAキット
• 競合ELISAキット
• 世界の前立腺特異抗原（PSA）検査市場、蛍光免疫測定法（FIA）のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ポイントオブケア FIA
• 実験室ベースのFIA
• 世界の前立腺特異抗原（PSA）検査市場、その他のタイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 化学発光免疫測定法（CLIA）
• 放射免疫測定法（RIA）

第7章 地域別・国別分析

• 世界の前立腺特異抗原（PSA）検査市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の前立腺特異抗原（PSA）検査市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 前立腺特異抗原（PSA）検査市場：競合情勢
• 前立腺特異抗原（PSA）検査市場：企業プロファイル
  • Siemens AG Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • Becton Dickinson and Company Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• PerkinElmer Inc.
• Beckman Coulter Inc.
• Bio-Rad Laboratories Inc.
• Ortho-Clinical Diagnostics Inc.
• DiaSorin SpA
• OPKO Health Inc.
• R&D Systems Inc.
• Meso Scale Diagnostics LLC
• Tosoh America Inc.
• Fujirebio Europe N.V.
• Boditech Med Inc.
• DRG International Inc.
• BioVision Inc.
• Enzo Life Sciences Inc.
• RayBiotech Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 前立腺特異抗原（PSA）検査市場2029：新たな機会を提供する国
• 前立腺特異抗原（PSA）検査市場2029：新たな機会を提供するセグメント
• 前立腺特異抗原（PSA）検査市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

The prostate-specific antigen (PSA) test is a blood test designed to measure the presence of prostate-specific antigen in the body. Its primary purpose is to screen for and monitor prostate cancer in men by assessing the levels of prostate-specific antigen in the bloodstream.

The main types of PSA tests include clinical laboratory improvement amendments (CLIA), enzyme-linked immunosorbent assay (ELISA), fluorescence immunoassay (FIA), and others. Clinical laboratory improvement amendments (CLIA) comprise a set of regulations governing laboratory testing, requiring clinical laboratories to obtain certification from the Centers for Medicare & Medicaid Services (CMS) before conducting diagnostic testing on human samples. These tests find applications in various areas, including screening and post-treatment monitoring, and are utilized by diverse end-users such as hospitals, diagnostic centers, research institutes, and others.

The prostate-specific antigen (PSA) test market research report is one of a series of new reports from The Business Research Company that provides prostate-specific antigen (PSA) test market statistics, including prostate-specific antigen (PSA) test industry global market size, regional shares, competitors with a prostate-specific antigen (PSA) test market share, detailed prostate-specific antigen (PSA) test market segments, market trends and opportunities, and any further data you may need to thrive in the prostate-specific antigen (PSA) test industry. This prostate-specific antigen (PSA) test market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The prostate specific antigen (PSA) test market size has grown rapidly in recent years. It will grow from $4.15 billion in 2024 to $4.66 billion in 2025 at a compound annual growth rate (CAGR) of 12.1%. The growth in the historic period can be attributed to increased awareness, aging population, medical advancements, clinical recommendations, pharmaceutical advancements

The prostate specific antigen (PSA) test market size is expected to see rapid growth in the next few years. It will grow to $7.29 billion in 2029 at a compound annual growth rate (CAGR) of 11.9%. The growth in the forecast period can be attributed to advancements in test accuracy, personalized medicine approach, personalized medicine approach, global aging population. Major trends in the forecast period include shift towards biomarker combinations, technological innovations, point-of-care testing, digital health integration, focus on early detection and prevention.

The projected expansion of the prostate-specific antigen (PSA) test market is fueled by the increasing incidence of prostate cancer. Prostate cancer, affecting the prostate gland in the male reproductive system, is a condition that warrants early detection and risk assessment. The PSA test serves as a prevalent screening tool for prostate cancer, measuring PSA levels in the bloodstream. Recent reports from the American Society of Clinical Oncology (ASCO) in March 2023 revealed that in the United States alone, an estimated 288,300 men were diagnosed with prostate cancer, with approximately 34,700 succumbing to the disease in 2023. Globally, it is anticipated that around 1,414,259 individuals will be diagnosed with prostate cancer in 2020. Consequently, the escalating prevalence of prostate cancer is a driving force behind the growth of the PSA test market.

The upswing in chronic diseases contributes to the burgeoning demand for PSA tests. Chronic diseases, characterized by prolonged medical conditions necessitating ongoing attention and management, include prostate cancer as one such condition. The PSA test emerges as a pivotal tool for screening, diagnosis, and monitoring the progression of prostate cancer. Predictions from the National Library of Medicine in 2022 anticipate a 99.5% rise in the number of individuals aged 50 and older with at least one chronic illness, reaching 142.66 million by 2050. Furthermore, the prevalence of multimorbidity is projected to increase by 91.16%, encompassing 14.968 million people in 2050. Hence, the upsurge in chronic diseases is poised to propel the PSA test market.

A prominent trend in the PSA test market is the integration of technological advancements. Key players in the market are actively developing advanced screening tools to maintain their competitive edge. LynxDx Inc., a US-based diagnostic company, exemplifies this trend with the launch of MyProstateScore 2.0 in February 2023. This non-invasive urine prostate cancer screening test employs 18 biomarkers, including the innovative gene fusion T2,ERG, for personalized risk assessment. MyProstateScore 2.0 not only delivers highly accurate, stratified risk assessment insights but also guides clinical decisions for patients exhibiting elevated PSA or abnormal digital rectal exam (DRE) findings.

Major companies in the PSA test market are focusing on product development and launches, such as home testing kits for PSA. Home testing kits, facilitating self-administered diagnostic procedures, offer convenience and accessibility. In September 2023, Randox, an Ireland-based health and toxicology company, unveiled an at-home testing kit for PSA. This kit enables individuals to measure PSA levels in their blood, providing indications of abnormalities within the prostate. Elevated PSA levels may signal various conditions, including an enlarged prostate, prostatitis, urinary tract infection, or the potential presence of prostate cancer.

In June 2024, AstraZeneca PLC, a biopharmaceutical company based in the UK, acquired Fusion Pharmaceuticals Inc. for an undisclosed sum. This acquisition is intended to enhance AstraZeneca PLC's advanced radioconjugate technology for more precise cancer treatments. Fusion Pharmaceuticals Inc. is a clinical-stage oncology company located in Canada that offers prostate-specific antigen (PSA) tests.

Major companies operating in the prostate specific antigen (PSA) test market include Siemens AG, F. Hoffmann-La Roche AG, Bayer AG, Abbott Laboratories, Becton Dickinson and Company, PerkinElmer Inc., Beckman Coulter Inc., Bio-Rad Laboratories Inc., Ortho-Clinical Diagnostics Inc., DiaSorin SpA, OPKO Health Inc., R&D Systems Inc., Meso Scale Diagnostics LLC, Tosoh America Inc., Fujirebio Europe N.V., Boditech Med Inc., DRG International Inc., BioVision Inc., Enzo Life Sciences Inc., RayBiotech Inc., Novus Biologicals LLC, Creative Diagnostics Inc., Elabscience, LifeSpan BioSciences Inc., American Laboratory Products Company Ltd., Accuquik Inc.

North America was the largest region in the prostate specific antigen (PSA) test market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the prostate specific antigen (psa) test market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the prostate specific antigen (psa) test market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The prostate-specific antigen (PSA) test market includes revenues earned by entities by providing services such as prostate cancer detection, monitoring, PSA screening, prostatitis evaluation, complex PSA tests, and blood tests. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Prostate Specific Antigen (PSA) Test Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on prostate specific antigen (psa) test market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for prostate specific antigen (psa) test ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The prostate specific antigen (psa) test market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Clinical Laboratory Improvement Amendments (CLIA); Enzyme-Linked Immunosorbent Assay (ELISA); Fluorescence Immunoassay (FIA); Other Types
• 2) By Application: Screening; Post-Treatment Monitoring; Other Applications
• 3) By End User: Hospitals; Diagnostic Centers; Research Institutes; Other End Users
• Subsegments:
• 1) By Clinical Laboratory Improvement Amendments (CLIA): CLIA Waived Tests; Non-CLIA Tests
• 2) By Enzyme-Linked Immunosorbent Assay (ELISA): Sandwich ELISA Kits; Competitive ELISA Kits
• 3) By Fluorescence Immunoassay (FIA): Point-Of-Care FIA; Laboratory-Based FIA
• 4) By Other Types: Chemiluminescent Immunoassay (CLIA); Radioimmunoassay (RIA)
• Companies Mentioned: Siemens AG; F. Hoffmann-La Roche AG; Bayer AG; Abbott Laboratories; Becton Dickinson and Company
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Prostate Specific Antigen (PSA) Test Market Characteristics

3. Prostate Specific Antigen (PSA) Test Market Trends And Strategies

4. Prostate Specific Antigen (PSA) Test Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Prostate Specific Antigen (PSA) Test Growth Analysis And Strategic Analysis Framework

• 5.1. Global Prostate Specific Antigen (PSA) Test PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Prostate Specific Antigen (PSA) Test Market Growth Rate Analysis
• 5.4. Global Prostate Specific Antigen (PSA) Test Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Prostate Specific Antigen (PSA) Test Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Prostate Specific Antigen (PSA) Test Total Addressable Market (TAM)

6. Prostate Specific Antigen (PSA) Test Market Segmentation

• 6.1. Global Prostate Specific Antigen (PSA) Test Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Clinical Laboratory Improvement Amendments (CLIA)
• Enzyme-Linked Immunosorbent Assay (ELISA)
• Fluorescence Immunoassay (FIA)
• Other Types
• 6.2. Global Prostate Specific Antigen (PSA) Test Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Screening
• Post-Treatment Monitoring
• Other Applications
• 6.3. Global Prostate Specific Antigen (PSA) Test Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Diagnostic Centers
• Research Institutes
• Other End Users
• 6.4. Global Prostate Specific Antigen (PSA) Test Market, Sub-Segmentation Of Clinical Laboratory Improvement Amendments (CLIA), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• CLIA Waived Tests
• Non-CLIA Tests
• 6.5. Global Prostate Specific Antigen (PSA) Test Market, Sub-Segmentation Of Enzyme-Linked Immunosorbent Assay (ELISA), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Sandwich ELISA Kits
• Competitive ELISA Kits
• 6.6. Global Prostate Specific Antigen (PSA) Test Market, Sub-Segmentation Of Fluorescence Immunoassay (FIA), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Point-Of-Care FIA
• Laboratory-Based FIA
• 6.7. Global Prostate Specific Antigen (PSA) Test Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chemiluminescent Immunoassay (CLIA)
• Radioimmunoassay (RIA)

7. Prostate Specific Antigen (PSA) Test Market Regional And Country Analysis

• 7.1. Global Prostate Specific Antigen (PSA) Test Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Prostate Specific Antigen (PSA) Test Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Prostate Specific Antigen (PSA) Test Market

• 8.1. Asia-Pacific Prostate Specific Antigen (PSA) Test Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Prostate Specific Antigen (PSA) Test Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Prostate Specific Antigen (PSA) Test Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Prostate Specific Antigen (PSA) Test Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Prostate Specific Antigen (PSA) Test Market

• 9.1. China Prostate Specific Antigen (PSA) Test Market Overview
• 9.2. China Prostate Specific Antigen (PSA) Test Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Prostate Specific Antigen (PSA) Test Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Prostate Specific Antigen (PSA) Test Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Prostate Specific Antigen (PSA) Test Market

• 10.1. India Prostate Specific Antigen (PSA) Test Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Prostate Specific Antigen (PSA) Test Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Prostate Specific Antigen (PSA) Test Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Prostate Specific Antigen (PSA) Test Market

• 11.1. Japan Prostate Specific Antigen (PSA) Test Market Overview
• 11.2. Japan Prostate Specific Antigen (PSA) Test Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Prostate Specific Antigen (PSA) Test Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Prostate Specific Antigen (PSA) Test Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Prostate Specific Antigen (PSA) Test Market

• 12.1. Australia Prostate Specific Antigen (PSA) Test Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Prostate Specific Antigen (PSA) Test Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Prostate Specific Antigen (PSA) Test Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Prostate Specific Antigen (PSA) Test Market

• 13.1. Indonesia Prostate Specific Antigen (PSA) Test Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Prostate Specific Antigen (PSA) Test Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Prostate Specific Antigen (PSA) Test Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Prostate Specific Antigen (PSA) Test Market

• 14.1. South Korea Prostate Specific Antigen (PSA) Test Market Overview
• 14.2. South Korea Prostate Specific Antigen (PSA) Test Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Prostate Specific Antigen (PSA) Test Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Prostate Specific Antigen (PSA) Test Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Prostate Specific Antigen (PSA) Test Market

• 15.1. Western Europe Prostate Specific Antigen (PSA) Test Market Overview
• 15.2. Western Europe Prostate Specific Antigen (PSA) Test Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Prostate Specific Antigen (PSA) Test Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Prostate Specific Antigen (PSA) Test Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Prostate Specific Antigen (PSA) Test Market

• 16.1. UK Prostate Specific Antigen (PSA) Test Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Prostate Specific Antigen (PSA) Test Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Prostate Specific Antigen (PSA) Test Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Prostate Specific Antigen (PSA) Test Market

• 17.1. Germany Prostate Specific Antigen (PSA) Test Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Prostate Specific Antigen (PSA) Test Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Prostate Specific Antigen (PSA) Test Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Prostate Specific Antigen (PSA) Test Market

• 18.1. France Prostate Specific Antigen (PSA) Test Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Prostate Specific Antigen (PSA) Test Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Prostate Specific Antigen (PSA) Test Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Prostate Specific Antigen (PSA) Test Market

• 19.1. Italy Prostate Specific Antigen (PSA) Test Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Prostate Specific Antigen (PSA) Test Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Prostate Specific Antigen (PSA) Test Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Prostate Specific Antigen (PSA) Test Market

• 20.1. Spain Prostate Specific Antigen (PSA) Test Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Prostate Specific Antigen (PSA) Test Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Prostate Specific Antigen (PSA) Test Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Prostate Specific Antigen (PSA) Test Market

• 21.1. Eastern Europe Prostate Specific Antigen (PSA) Test Market Overview
• 21.2. Eastern Europe Prostate Specific Antigen (PSA) Test Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Prostate Specific Antigen (PSA) Test Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Prostate Specific Antigen (PSA) Test Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Prostate Specific Antigen (PSA) Test Market

• 22.1. Russia Prostate Specific Antigen (PSA) Test Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Prostate Specific Antigen (PSA) Test Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Prostate Specific Antigen (PSA) Test Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Prostate Specific Antigen (PSA) Test Market

• 23.1. North America Prostate Specific Antigen (PSA) Test Market Overview
• 23.2. North America Prostate Specific Antigen (PSA) Test Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Prostate Specific Antigen (PSA) Test Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Prostate Specific Antigen (PSA) Test Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Prostate Specific Antigen (PSA) Test Market

• 24.1. USA Prostate Specific Antigen (PSA) Test Market Overview
• 24.2. USA Prostate Specific Antigen (PSA) Test Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Prostate Specific Antigen (PSA) Test Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Prostate Specific Antigen (PSA) Test Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Prostate Specific Antigen (PSA) Test Market

• 25.1. Canada Prostate Specific Antigen (PSA) Test Market Overview
• 25.2. Canada Prostate Specific Antigen (PSA) Test Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Prostate Specific Antigen (PSA) Test Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Prostate Specific Antigen (PSA) Test Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Prostate Specific Antigen (PSA) Test Market

• 26.1. South America Prostate Specific Antigen (PSA) Test Market Overview
• 26.2. South America Prostate Specific Antigen (PSA) Test Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Prostate Specific Antigen (PSA) Test Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Prostate Specific Antigen (PSA) Test Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Prostate Specific Antigen (PSA) Test Market

• 27.1. Brazil Prostate Specific Antigen (PSA) Test Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Prostate Specific Antigen (PSA) Test Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Prostate Specific Antigen (PSA) Test Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Prostate Specific Antigen (PSA) Test Market

• 28.1. Middle East Prostate Specific Antigen (PSA) Test Market Overview
• 28.2. Middle East Prostate Specific Antigen (PSA) Test Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Prostate Specific Antigen (PSA) Test Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Prostate Specific Antigen (PSA) Test Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Prostate Specific Antigen (PSA) Test Market

• 29.1. Africa Prostate Specific Antigen (PSA) Test Market Overview
• 29.2. Africa Prostate Specific Antigen (PSA) Test Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Prostate Specific Antigen (PSA) Test Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Prostate Specific Antigen (PSA) Test Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Prostate Specific Antigen (PSA) Test Market Competitive Landscape And Company Profiles

• 30.1. Prostate Specific Antigen (PSA) Test Market Competitive Landscape
• 30.2. Prostate Specific Antigen (PSA) Test Market Company Profiles
  • 30.2.1. Siemens AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Becton Dickinson and Company Overview, Products and Services, Strategy and Financial Analysis

31. Prostate Specific Antigen (PSA) Test Market Other Major And Innovative Companies

• 31.1. PerkinElmer Inc.
• 31.2. Beckman Coulter Inc.
• 31.3. Bio-Rad Laboratories Inc.
• 31.4. Ortho-Clinical Diagnostics Inc.
• 31.5. DiaSorin SpA
• 31.6. OPKO Health Inc.
• 31.7. R&D Systems Inc.
• 31.8. Meso Scale Diagnostics LLC
• 31.9. Tosoh America Inc.
• 31.10. Fujirebio Europe N.V.
• 31.11. Boditech Med Inc.
• 31.12. DRG International Inc.
• 31.13. BioVision Inc.
• 31.14. Enzo Life Sciences Inc.
• 31.15. RayBiotech Inc.

32. Global Prostate Specific Antigen (PSA) Test Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Prostate Specific Antigen (PSA) Test Market

34. Recent Developments In The Prostate Specific Antigen (PSA) Test Market

35. Prostate Specific Antigen (PSA) Test Market High Potential Countries, Segments and Strategies

• 35.1 Prostate Specific Antigen (PSA) Test Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Prostate Specific Antigen (PSA) Test Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Prostate Specific Antigen (PSA) Test Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer